IBRX News and Press, ImmunityBio Inc. From 11/10/23

ImmunityBio Inc. (IBRX) is expected to report $-0.27 for Q3 2023

Findings from NCI-led study suggest that Memory Cytokine-Enriched Natural Killer cells (M-ceNK) may provide benefit to patients with small cell lung cancer and patients with other types of neuroendocrine tumors M-ceNK may provide an additional line of therapy in other cases of immunologically...

2023-10-30 12:16:36 ET DENVER, Colo., Oct. 30, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; VYNE Therapeutics Inc (NASDAQ: VYNE), Coherus BioSciences Inc (NASDAQ: CHRS), MeiraGTx Holdings PLC (N...

2023-10-30 10:00:42 ET More on Health Care Select Sector SPDR Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare (XLV) Stocks to watch in the Health Care sector as earnings close in BofA reports 10th consecutive week of equity inflows For further...

2023-10-28 03:41:28 ET Summary ImmunityBio is seeking approval for their vaccine Anktiva, which is being assessed for non-muscle invasive bladder cancer. The company faced setbacks with their FDA submission, but recently announced a resubmission that was accepted. ImmunityBio'...

2023-10-27 10:02:45 ET More on Health Care Select Sector SPDR Health Care Select Sector Fund ETF: Riding The Healthcare Boom Stocks to watch in the Health Care sector as earnings close in BofA reports 10th consecutive week of equity inflows For further detail...

2023-10-26 12:48:21 ET More on ImmunityBio ImmunityBio: The CRL Makes It Riskier Than Ever ImmunityBio: Ongoing Dilution And Regulatory Uncertainties Blur Investment Prospects ImmunityBio extends gains on surging volumes after regulatory update ImmunityBio an...

2023-10-26 09:56:33 ET More on Health Care Select Sector SPDR Health Care Select Sector Fund ETF: Riding The Healthcare Boom Stocks to watch in the Health Care sector as earnings close in BofA reports 10th consecutive week of equity inflows For further detail...

BLA for N-803 plus BCG in high-risk non-muscle-invasive bladder cancer (NMIBC) was resubmitted to the Agency on October 23, 2023 A new PDUFA date of April 23, 2024 has been communicated by the Agency ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today ann...

2023-10-24 14:38:06 ET Summary ImmunityBio, Inc.'s drug Anktiva received a Complete Response Letter, or CRL, from the FDA, delaying its approval for the treatment of NMIBC. The CRL was related to deficiencies in the FDA's inspection of the company's third-party contract manufactur...